Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ketamine racemic intranasal - Seelos Therapeutics

Drug Profile

Ketamine racemic intranasal - Seelos Therapeutics

Alternative Names: Ereska; IN Ketamine; Intranasal ketamine; Intranasal raceamic ketamine; PMI-100; PMI-150; SLS-002; TUR-002

Latest Information Update: 24 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Unknown
  • Developer Hospira; Seelos Therapeutics
  • Class Analgesics; Antidepressants; Cyclohexanes; General anaesthetics; Small molecules
  • Mechanism of Action AMPA receptor agonists; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Suicidal ideation
  • Discontinued Acute pain; Cancer pain

Most Recent Events

  • 21 Oct 2019 Seelos Therapeutics amends its purchase agremment with Vyera Pharmaceuticals for the development of SLS 002 (The necessity to conduct prospective phase III trial is precluded)
  • 21 Oct 2019 Seelos Therapeutics plans a phase II proof of concept (PoC) trial (following type C meeting with the US FDA) in Suicidal ideation in major depressive disorder (MDD)
  • 21 May 2019 Seelos Therapeutics plans a PK/PD, drug-drug interaction-based phase-I trial for Suicidal ideation (In volunteers) (Intranasal) in Q3 2019 under IND programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top